Carvana (CVNA) significantly outperformed expectations in Q2 2025, reporting earnings of $1.28 per share against an estimated $1.10 and revenues of $4.84 billion, a 42% year-over-year increase that beat consensus by 5.62%. The company achieved an adjusted EBITDA of $601 million with a 12.4% margin and projects full-year 2025 adjusted EBITDA between $2-$2.2 billion, a substantial increase from 2024. Despite these strong financial results and upward estimate revisions, CVNA shares have declined 3.3% since the report, underperforming the S&P 500, with analysts maintaining a Zacks Rank #3 (Hold) and expecting an in-line return.
Carvana (CVNA) delivered a robust second-quarter 2025 performance, significantly surpassing consensus estimates with earnings of $1.28 per share and revenue of $4.84 billion, a 42% year-over-year increase. The outperformance was broad-based, fueled by a 41.2% rise in retail vehicle sales and a 44.5% increase in wholesale units, both exceeding forecasts. Profitability metrics also showed marked improvement, with total gross profit climbing 49% to $1.06 billion and adjusted EBITDA margin expanding to 12.4% from 10.4% in the prior-year quarter. Management provided strong forward guidance, projecting a sequential rise in Q3 retail sales and raising full-year 2025 adjusted EBITDA to a range of $2-$2.2 billion. Despite these positive fundamentals and an upward 5.65% revision in consensus estimates, the stock has paradoxically declined 3.3% in the month following the report, underperforming the S&P 500. This divergence may be explained by subtle weaknesses, including misses on internal expectations for retail and 'other' gross profit per unit, and a stock profile that, while scoring an 'A' for Growth, is rated 'D' for Momentum and 'F' for Value, culminating in a Zacks Rank #3 (Hold) that suggests an in-line return is expected.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment